EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

The Association of Epstein–Barr Virus Donor and Recipient Serostatus With Outcomes After Kidney Transplantation

Vishnu S Potluri iD, Siqi Zhang iD, Douglas E Schaubel iD, Salma Shaikhouni iD, Emily A Blumberg, Sunita D Nasta, Roy D Bloom iD, Massiel Cruz-Peralta, Rajil B Mehta iD, Nikhil R Lavu, Bereket Getachew, Srijan Tandukar iD und 2 weitere

Annals of Internal Medicine · 2025

DOI: 10.7326/annals-24-00165 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Internal Medicine, 2025. Verfasst von Vishnu S Potluri und 13 weiteren Autor:innen. Beteiligte Einrichtung: Renal-Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, and Center for Clinical Epidemiology and Biostatistics, Univ…. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Herpesvirus 4, Human, Kidney Transplantation, Lymphoproliferative Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Prior studies indicate that 1% to 4% of Epstein-Barr virus (EBV)-seronegative recipients of EBV-seropositive donor (EBV D+/R-) kidneys develop posttransplant lymphoproliferative disorder (PTLD). However, these estimates are based on limited data that lack granularity. OBJECTIVE: To determine the associations between pretransplant EBV D+/R- and recipient EBV-seropositive status (R+) and the outcomes of PTLD and graft and patient survival among adult kidney transplant recipients. DESIGN: Retrospective cohort study. SETTING: Two large U.S. transplant centers. PARTICIPANTS: Epstein-Barr virus D+/R- and EBV R+ recipients matched 1:3 on donor, recipient, and transplant characteristics between 1 January 2010 and 30 June 2022. MEASUREMENTS: Exposure was pretransplant donor and recipient EBV serostatus. The primary outcome was biopsy-proven PTLD. Secondary outcomes were all-cause graft loss (death, retransplant, or graft failure) and death. Follow-up was truncated to 3 years after transplant. RESULTS: The final cohort comprised 104 EBV D+/R- recipients matched to 312 EBV R+ recipients. The mean age was 42 years (SD, 17.1), 59% were living donor transplants, and 95% received thymoglobulin induction. Among EBV D+/R- recipients, 50 (48.1%) developed EBV DNAemia, with a median time of 198 days (IQR, 110 to 282 days) after transplantation. Posttransplant lymphoproliferative disorder occurred in 23 (22.1%) EBV D+/R- recipients at a median of 202 days (IQR, 118 to 317 days) after transplantation. Epstein-Barr virus D+/R- recipients had higher all-cause graft failure (hazard ratio, 2.21 [95% CI, 1.06 to 4.63]); mortality was higher but not statistically significant (hazard ratio, 2.19 [CI, 0.94 to 5.13]). LIMITATION: Two-center study. CONCLUSION: Compared with previous studies, this study showed that EBV D+/R- kidney recipients face a 5- to 10-fold higher cumulative incidence of PTLD. Strategies to mitigate the PTLD risk are urgently needed. PRIMARY FUNDING SOURCE: National Institutes of Health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus InfectionsHerpesvirus 4, HumanKidney TransplantationLymphoproliferative DisordersPostoperative ComplicationsTissue DonorsAdultFemaleHumansMaleMiddle AgedGraft SurvivalRetrospective StudiesYoung Adult

Autor:innen und Institutionen

  • Renal-Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania (V.S.P.).
  • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania (S.Z., D.E.S.).
  • Renal-Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (S.S., R.D.B., S.T.).
  • Division of Infectious Disease, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (E.A.B.).
  • Division of Hematology and Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (S.D.N.).
  • Renal-Electrolyte Division, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (M.C.-P., R.B.M., C.M.P.).

ORCID-Profile: Vishnu S Potluri, Siqi Zhang, Douglas E Schaubel, Salma Shaikhouni, Roy D Bloom, Rajil B Mehta, Srijan Tandukar

Förderung

  • NIDDK NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Potluri, V. S., Zhang, S., Schaubel, D. E., Shaikhouni, S., Blumberg, E. A., Nasta, S. D., Bloom, R. D., Cruz-Peralta, M., Mehta, R. B., Lavu, N. R., Getachew, B., Tandukar, S., Reese, P. P., & Puttarajappa, C. M. (2025). The Association of Epstein–Barr Virus Donor and Recipient Serostatus With Outcomes After Kidney Transplantation. Annals of Internal Medicine. https://doi.org/10.7326/annals-24-00165

Vancouver

Potluri VS, Zhang S, Schaubel DE, Shaikhouni S, Blumberg EA, Nasta SD, et al. The Association of Epstein–Barr Virus Donor and Recipient Serostatus With Outcomes After Kidney Transplantation. Annals of Internal Medicine. 2025. doi:10.7326/annals-24-00165

BibTeX
@article{Potluri2025,
  author = {Potluri, Vishnu S and Zhang, Siqi and Schaubel, Douglas E and Shaikhouni, Salma and Blumberg, Emily A and Nasta, Sunita D and Bloom, Roy D and Cruz-Peralta, Massiel and Mehta, Rajil B and Lavu, Nikhil R and Getachew, Bereket and Tandukar, Srijan and Reese, Peter P and Puttarajappa, Chethan M},
  title = {The Association of Epstein–Barr Virus Donor and Recipient Serostatus With Outcomes After Kidney Transplantation},
  journal = {Annals of Internal Medicine},
  year = {2025},
  doi = {10.7326/annals-24-00165}
}
Kostenlos starten →